Pityriasis rubra pilaris is a rare inflammatory disorder characterized by follicular papules on an erythematous base often exhibiting islands of unaffected skin, follicular plugging, and palmoplantar hyperkeratosis. While vitamin A deficiency and autoimmune reactions have been hypothesized as possible etiologies of this condition, pityriasis rubra pilaris-like eruptions secondary to medications are extremely rare. To our knowledge, only three other cases have been reported, and pityriasis rubra pilaris has never been reported in association with bevacizumab. We present a 70-year-old man who developed erythroderma both clinically and histologically consistent with pityriasis rubra pilaris 10 days after intravitreal injection of bevacizumab for age-related macular degeneration. As immune-modulating drugs grow in their application for a host of diseases, recognition of associated medication complications is important. P ityriasis rubra pilaris (PRP) is a collection of chronic exfoliative disorders of unknown origin. It is characterized by diff use, well-circumscribed red-orange or salmon-colored erythroderma that typically progresses in a cranial-caudal fashion, with distinct areas of clearing termed "islands of sparing." It is also associated with follicular plugging and palmoplantar keratoderma with edema. Possible etiologies include vitamin A defi ciency, internal malignancy, infection, and abnormal immunologic responses. PRP is considered a rare cause of erythroderma, manifested by redness and scaling of over 90% of skin body surface area; however, PRP has a particular histologic and clinical appearance that sets it apart from other erythrodermic states ( Table 1 ) . Histologically, PRP resembles a checkerboard with alternating areas of orthokeratosis and parakeratosis. While nondiagnostic, this pattern in association with follicular plugging and epidermal acanthosis is highly suggestive of PRP. Most cases of PRP are chronic and treatment is highly variable; however, PRP rarely responds to corticosteroids.
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Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor that is approved for monthly intravitreal injections in age-related macular degeneration. As many as 19% of patients experience exfoliative dermatitis secondary to bevacizumab when it is delivered by either an intravenous or intravitreal route ( 1 ); however, a PRP-like reaction has never been reported. 
CASE REPORT
A 70-year-old Caucasian man presented to the dermatology clinic with a 10-day history of exfoliative dermatitis. It began as a burning sensation on the scalp and quickly progressed to diff use erythema and edema with intense pruritus. He had received prednisone in the emergency department 4 days prior to his clinic visit, which signifi cantly improved his symptoms. Two weeks before presenting to the dermatology clinic, the patient received an intravitreal injection of bevacizumab for a new diagnosis of age-related macular degeneration. He denied a history of known drug allergies or previous adverse dermatologic reactions to medications. Of note, he did have a history of malignant melanoma that was excised from the right forearm in 2008, with no signs of recurrence. His past medical history was signifi cant for hypertension and hypercholesterolemia, for which he took valsartan and simvastatin.
On initial exam, he had an erythematous, scaly, exfoliative erythroderma with "islands of sparing" aff ecting the face, scalp, trunk, hands, and feet ( Figure 1 ) Basic laboratory results were normal. He returned to the clinic 1 week later complaining of worsening symptoms when the prednisone dose was tapered. At that time, he had signifi cant erythema and scaling of the scalp and face, extending onto the neck. Additionally, his palms and soles had large patches of erythema and signifi cant scaling ( Figure 2 ) . A 4 mm punch biopsy from the right postauricular neck was performed showing foci of parakeratosis and follicular plugging consistent with PRP. Th e biopsy also showed a superfi cial perivascular infi ltrate of lymphocytes with eosinophils, more consistent with a druginduced eruption. Given his recent initiation of bevacizumab, clinical presentation, and histopathological fi ndings, the diagnosis was considered to be a PRP-like eruption secondary to bevacizumab. He was switched to a higher prednisone taper and prescribed clobetasol 0.05% ointment. He showed great improvement with this combination of systemic and topical corticosteroids within 2 weeks.
DISCUSSION
Cutaneous adverse reactions to bevacizumab are not uncommon; however, this is the fi rst reported case of a PRP-like reaction induced by an intravitreal injection of bevacizumab. Since the pathogenesis of primary PRP is unclear, we were unable to completely rule out other possible causes such as solid organ malignancy and infection. Nonetheless, our patient's rapid clinical improvement with topical and systemic steroids, along with the presence of eosinophils on histopathology, suggests a drug-induced reaction over primary PRP.
Th ree similar cases of PRP-like drug reactions have recently been reported. Th e fi rst was induced by sorafenib, a multitargeted kinase inhibitor ( 2 ) . Sorafenib, like bevacizumab, is known to inhibit angiogenesis through vascular endothelial growth factor. It is possible that by inhibiting this signaling pathway, downstream eff ects of cell proliferation are altered, leading to a unique cutaneous reaction. PRP-like reactions have also been reported with telaprevir, a protease inhibitor, and imatinib, a kinase inhibitor ( 3 , 4 ) . Similar to our case, these reported cases of PRP-like drug eruptions resolved quickly with treatment, in contrast to primary PRP, which is usually persistent. Physicians should be aware that PRP-like drug reactions are occurring more frequently and may be associated with intravitreal injections of bevacizumab. 
